Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2026)

Amphastar Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 143.53% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $14.4 million (up 143.53% YoY), while the FY2025 annual figure was $14.5 million, up 40.78% from the prior year.
• Long-Term Investments was $14.4 million for Q1 2026 at Amphastar Pharmaceuticals, down from $14.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $15.2 million in Q1 2024 to a low of $527000.0 in Q4 2023.
• Historically, Long-Term Investments has averaged $7.6 million across 5 years, with a median of $5.9 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments plunged 88.29% in 2023, then surged 1854.46% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $4.5 million in 2022, then slumped by 88.29% to $527000.0 in 2023, then soared by 1854.46% to $10.3 million in 2024, then soared by 40.78% to $14.5 million in 2025, then declined by 0.69% to $14.4 million in 2026.
• The last three Long-Term Investments figures came in at $14.4 million (Q1 2026), $14.5 million (Q4 2025), and $13.3 million (Q3 2025), per Business Quant data.